Search results
Biogen is buying up an immune drug developer for $1.8 billion
Quartz· 2 days agoBiotechnology giant Biogen said on Wednesday that it is acquiring immune drug developer Human...
FDA grants Cartesian Therapeutics RMAT status for MG therapy By Investing.com
Investing.com· 2 days agoCartesian Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food...
Earnings call: Longeveron reports Q1 2024 results, optimistic on Lomecel-B
Investing.com· 6 days agoLongeveron Inc. (LGVN), a leader in regenerative medicine, recently discussed its first-quarter...
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and...
Morningstar· 6 days agoInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis - 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 15 hours agoThe study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, as well as finding effective doses in various treatment-resistant ...
Octapharma USA Appoints New VP of Commercial Marketing & Development
New Jersey Business Magazine· 4 days agoOctapharma USA, Inc. has appointed pharmaceutical industry veteran Kelly Hearn as vice president of...
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement - Kazia...
Benzinga· 17 hours agoKazia Therapeutics Limited KZIA (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum ...
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Morningstar· 5 days agoAmgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive ...
Q1 2024 Biomx Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 2 days agoIn January this year, we were granted Orphan Drug Designation by the FDA for BX004. More recently, in April, we presented positive safety and efficacy results ...
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks· 1 day agoFree Report) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead pipeline candidate, Descartes-08, for the treatment of myasthenia gravis ...
